Abstract

FORMULATION AND EVALUATION OF SUSTAINED RELEASE MATRIX TABLET OF TOFACITINIB CITRATE

Kavaji Bhale* and Khanderao Jadhav

Abstract

In this study, an effort was made to develop tofacitinib citrate extended-release tablets to provide an extended-release dosage form, in order to improve efficacy, reduce total dose frequency, and improve rates survive. Patient satisfaction. Infrared spectroscopy and differential scanning calorimetry confirmed that there were no drugpolymer interactions. In this study, tofacitinib citrate sustained-release tablets were prepared by a hot granulation technique using carnauba wax, cetyl alcohol, and stearic acid as slow-release polymers. In this work, only physicochemical characteristics such as reset angle, Carr index, Hausner ratio, weight change, hardness, thickness, friability and drug content were performed and only evaluation was performed. print studies. in vitro of tofacitinib citrate matrix tablets. Along with in vitro studies, in vivo drug research is the most important. In the future, in vivo studies are needed to establish the in vitro-in vivo correlation (IVIVC) required for formulation development and long-term stability studies are needed. All tests show that the particles exhibit excellent flow characteristics. In the present studies, the F3 substrate formulation containing carnauba wax may exhibit maximal delay in drug release and an abnormal diffusion mechanism. For these reasons, the F3 formula is considered the best of the nine formulas.

Keywords: Tofacitinib citrate, Sustained Release, Matrix tablet, DSC.